Company intelligence / Profile preview

MD Matrix

West Sacramento, California, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

The company received FDA 510(k) clearance for its Osteo-PTM Bone Graft Substitute, a product based on hyper-crosslinked carbohydrate polymers. This technology enables bone regeneration by providing a scaffold structure that recruits the body’s own cells to heal bone defects. The product is being adopted in orthopedic, spine, and trauma care, with a focus on faster and more natural healing

Therapeutic areas: Rheumatology
Modalities: DeviceSynthetic bone graft substitute
Industry: Implantable Medical Devices

Partnerships

Supported by University of California, Davis (technology transfer, guidance, and possible early investment)

Beyond the preview

Go deeper on MD Matrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD Matrix.

Explore the full profile